Medical Affairs

Congress posters & Presentations

Congress materials from Beren-sponsored research

Presentation
Biomarkers
NPCCSS
Survival Analysis
Presentation: Survival, Clinical, and Biomarker Data Support the Efficacy of Intrathecal Adrabetadex in Niemann-Pick Disease Type C​

March 12, 2026

American College of Medical Genetics and Genomics 2026
ePoster
NPCCSS
Survival Analysis
Substantial Survival Benefit and Slowing of Disease Progression With Adrabetadex Treatment in Individuals With Infantile-onset Niemann-pick Disease Type C (NPC)

February 6, 2026

WORLDSymposium 2026
Poster
NPCCSS
Survival Analysis
Substantial Survival Benefit and Slowing of Disease Progression With Adrabetadex Treatment in Individuals With Infantile-onset Niemann-pick Disease Type C (NPC)

February 6, 2026

WORLDSymposium 2026
ePoster
Biomarkers
Adrabetadex Treatment in Individuals With Niemann-Pick Disease Type C1 Re-establishes Cholesterol Trafficking, Resulting in Decreased Markers of Neuronal Damage and Cell Death

February 6, 2026

WORLDSymposium 2026
Presentation
Biomarkers
Adrabetadex Treatment in Individuals With Niemann-Pick Disease Type C1 Re-establishes Cholesterol Trafficking, Resulting in Decreased Markers of Neuronal Damage and Cell Death

February 6, 2026

WORLDSymposium 2026
Poster
Biomarkers
Adrabetadex Treatment in Individuals With Niemann-Pick Disease Type C1 Re-establishes Cholesterol Trafficking, Resulting in Decreased Markers of Neuronal Damage and Cell Death

February 6, 2026

WORLDSymposium 2026
Poster
Survival Analysis
Substantial Survival Benefit in Individuals with Infantile-onset Niemann-Pick Disease Type C Treated with Adrabetadex

October 10, 2025

Child Neurology Society 2025
Poster
Biomarkers
Restoration of Cholesterol Trafficking Results in Decreased Markers of Neuronal Damage in Individuals with Niemann-Pick Disease Type C1

October 10, 2025

Child Neurology Society 2025
Poster
Survival Analysis
Substantial Survival Benefit in Individuals with Infantile-onset Niemann-Pick Disease Type C Treated with Adrabetadex

September 14, 2025

American Neurological Association 2025
Poster
Biomarkers
Restoration of Cholesterol Trafficking Results in Decreased Markers of Neuronal Damage in Individuals with Niemann-Pick Disease Type C1

September 14, 2025

American Neurological Association 2025

Contact Beren Medical

If you have additional questions related to information provided on this website or other medical inquiries, please contact the Beren Medical Affairs team at medinfo@berentx.com.

The information provided on this website is provided by the Beren Therapeutics P.B.C. (“Beren”) Medical Affairs team for healthcare professionals in the US. It is designed to provide self-service access to medical information and medical affairs content about Beren products, pipeline, and therapeutic areas of interest including clinical data, research developments, congress materials, and publications. Certain materials such as posters and presentations presented in this website are a result of Beren-sponsored research and are not intended to be a comprehensive overview of all information and materials presented at a particular congress. The website is intended to provide scientifically balanced information and educational resources and may include information related to products or indications that have not been approved by the US Food and Drug Administration. The information provided is not intended as medical advice and does not replace independent medical judgement. By searching this website, you confirm the unsolicited nature of your inquiry. Please confirm that you agree and that you are a registered healthcare professional registered to practice in the US.

Are you a US healthcare provider?

No